Prevention of postmenopausal bone loss and endometrial responses during a two year prospective study with transdermal 17 beta-estradiol and oral medroxyprogesterone acetate.
Fioretti
P
P
Department of Obstetrics and Gynecology, University of Pisa, School of Medicine, Italy.
Gambacciani
M
M
Spinetti
A
A
Cagnacci
A
A
Paoletti
A M
AM
Felipetto
R
R
Melis
G B
GB
D000279:Administration, Cutaneous; D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004717:Endometrium / Q000187:drug effects* / Q000502:physiology; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy / Q000517:prevention & control*
D000970:Antineoplastic Agents; D004958:Estradiol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone